"Eat me" imaging and therapy

Advanced Drug Delivery Reviews

Volumn 99, Issue , 2016, Pages 2-11

  Bagalkot, Vaishali ^a   Deiuliis, Jeffrey A ^a   Rajagopalan, Sanjay ^a   Maiseyeu, Andrei ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; Imaging; Immune response; Leukocytes; Liposomes; Phagocytes; Phosphatidylserine

Indexed keywords

DRUG DELIVERY; IMAGING TECHNIQUES; IMMUNE SYSTEM; LIPOSOMES; MEDICAL APPLICATIONS; NANOPARTICLES; PATHOLOGY; TARGETED DRUG DELIVERY;

ANTI-INFLAMMATORIES; BIOMEDICAL APPLICATIONS; IMMUNE RESPONSE; IMMUNO MODULATIONS; INNATE IMMUNE SYSTEMS; LEUKOCYTES; PHAGOCYTES; PHOSPHATIDYLSERINE;

CONTROLLED DRUG DELIVERY;

ANTIINFLAMMATORY AGENT; NANOPARTICLE; PHOSPHATIDYLSERINE; DRUG; DRUG CARRIER;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CONTRAST ENHANCEMENT; DRUG DELIVERY SYSTEM; ECHOGRAPHY; GENE TARGETING; GENE VECTOR; HUMAN; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; DIAGNOSTIC IMAGING; DRUG THERAPY; INNATE IMMUNITY;

ANIMALS; DIAGNOSTIC IMAGING; DRUG CARRIERS; DRUG THERAPY; HUMANS; IMMUNITY, INNATE; PHARMACEUTICAL PREPARATIONS; PHOSPHATIDYLSERINES;

EID: 84960409993     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.01.009     Document Type: Review

References (135)

1. Henson P.M., Hume D.A. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 2006, 27(5):244-250.
2. Lauber K., et al. Clearance of Apoptotic Cells: Getting Rid of the Corpses. Mol. Cell 2004, 14(3):277-287.
3. Fuchs Y., Steller H. Programmed cell death in animal development and disease. Cell 2011, 147(4):742-758.
4. Bianchi M.E. DAMPs, PAMPs and alarmins: All we need to know about danger. J. Leukoc. Biol. 2007, 81(1):1-5.
5. Rosin D.L., Okusa M.D. Dangers within: DAMP responses to damage and cell death in kidney disease. J. Am. Soc. Nephrol. 2011, 22(3):416-425.
6. Elliott M.R., et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461(7261):282-286.
7. Chekeni F.B., et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 2010, 467(7317):863-867.
8. Lauber K., et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003, 113(6):717-730.
9. Truman L.A., et al. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 2008, 112(13):5026-5036.
10. Hochreiter-Hufford A., Ravichandran K.S. Clearing the dead: Apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb. Perspect. Biol. 2013, 5(1).
11. Campisi L., Cummings R.J., Blander J.M. Death-defining immune responses after apoptosis. Am. J. Transplant. 2014, 14(7):1488-1498.
12. Poon I.K.H., et al. Apoptotic cell clearance: Basic biology and therapeutic potential. Nat. Rev. Immunol. 2014, 14(3):166-180.
13. Ravichandran K.S. Beginnings of a good apoptotic meal: The find-me and eat-me signaling pathways. Immunity 2011, 35(4):445-455.
14. Poon I.K., et al. Apoptotic cell clearance: Basic biology and therapeutic potential. Nat. Rev. Immunol. 2014, 14(3):166-180.
15. Narula J., et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med. 2001, 7(12):1347-1352.
16. Isobe S., et al. Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. J. Nucl. Med. 2006, 47(9):1497-1505.
17. Laufer E.M., et al. PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled annexin A5. Q. J. Nucl. Med. Mol. Imaging 2009, 53(1):26-34.
18. Kolodgie F.D., et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: A technique with potential for noninvasive imaging of vulnerable plaque. Circulation 2003, 108(25):3134-3139.
19. Zhou H., et al. Phosphatidylserine-targeted molecular imaging of tumor vasculature by magnetic resonance imaging. J. Biomed. Nanotechnol. 2014, 10(5):846-855.
20. Zhang L., et al. Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice. J. Control. Release 2014, 183:114-123.
21. Wuest M., et al. Radiopharmacological evaluation of f-labeled phosphatidylserine-binding peptides for molecular imaging of apoptosis. Nucl. Med. Biol. 2015.
22. Li J., et al. Characterization of (18)F-dipicolylamine (DPA) derivatives in cells infected with influenza virus. Nucl. Med. Biol. 2015, 42(3):283-291.
23. Fischer U., Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005, 12(Suppl. 1):942-961.
24. Peer D. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 2012, 64(15):1738-1748.
25. Krysko O., et al. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013, 4:e631.
26. Peer D. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 2012, 64(15):1738-1748.
27. Krysko D.V., et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 2012, 12(12):860-875.
28. Bratton D.L., et al. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J. Biol. Chem. 1997, 272(42):26159-26165.
29. Hankins H.M., et al. Role of flippases, scramblases and transfer proteins in phosphatidylserine subcellular distribution. Traffic 2015, 16(1):35-47.
30. Fadok V.A., et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 1992, 148(7):2207-2216.
31. Kuypers F.A., et al. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood 1996, 87(3):1179-1187.
32. Kuypers F.A., et al. Membrane phospholipid asymmetry in human thalassemia. Blood 1998, 91(8):3044-3051.
33. Wilson M.J., Richter-Lowney K., Daleke D.L. Hyperglycemia induces a loss of phospholipid asymmetry in human erythrocytes. Biochemistry 1993, 32(42):11302-11310.
34. Huynh M.-L.N., Fadok V.A., Henson P.M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J. Clin. Investig. 2002, 109(1):41-50.
35. Shi D., et al. Artificial phosphatidylserine liposome mimics apoptotic cells in inhibiting maturation and immunostimulatory function of murine myeloid dendritic cells in response to 1-chloro-2,4-dinitrobenze in vitro. Arch. Dermatol. Res. 2007, 299(7):327-336.
36. Stuart L.M., et al. Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J. Immunol. 2002, 168(4):1627-1635.
37. Ramos G.C., et al. Apoptotic mimicry: Phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator-activated receptors (PPARs) in vivo. Br. J. Pharmacol. 2007, 151(6):844-850.
38. Posadas I., et al. Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br. J. Pharmacol. 2004, 142(2):331-338.
39. Harel-Adar T., et al. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(5):1827-1832.
40. Dvoriantchikova G., et al. Phosphatidylserine-containing liposomes promote maximal survival of retinal neurons after ischemic injury. J. Cereb. Blood Flow Metab. 2009, 29(11):1755-1759.
41. Hashioka S., et al. Phosphatidylserine and phosphatidylcholine-containing liposomes inhibit amyloid beta and interferon-gamma-induced microglial activation. Free Radic. Biol. Med. 2007, 42(7):945-954.
42. Greco E., et al. Janus-faced liposomes enhance antimicrobial innate immune response in mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(21):E1360-E1368.
43. Wu Z., et al. Phosphatidylserine-containing liposomes inhibit the differentiation of osteoclasts and trabecular bone loss. J. Immunol. 2010, 184(6):3191-3201.
44. Ma H.M., Wu Z., Nakanishi H. Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages. Lab. Investig. 2011, 91(6):921-931.
45. Olowokure O., Qi X. Pancreatic cancer: Current standards, working towards a new therapeutic approach. Expert. Rev. Anticancer. Ther. 2014, 14(5):495-497.
46. Chu Z., et al. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PLoS One 2013, 8(10):e75507.
47. Lu K., et al. Toll-like receptor 4 can recognize SapC-DOPS to stimulate macrophages to express several cytokines. Inflamm. Res. 2011, 60(2):153-161.
48. Zhang X.Q., et al. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Adv. Healthcare Mater. 2015, 4(2):228-236.
49. Romero G., et al. Lipid layer engineering of poly(lactide-co-glycolide) nanoparticles to control their uptake and intracellular co-localisation. J. Mater. Chem. B 2013, 1(17):2252.
50. Bagalkot V., et al. Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals. J. Control. Release 2015, 217:243-255.
51. Yotsumoto S., et al. Induction of antigen-dependent interleukin-12 production by negatively charged liposomes encapsulating antigens. Vaccine 2004, 22(25-26):3503-3509.
52. Yotsumoto S., Kakiuchi T., Aramaki Y. Enhancement of IFN-gamma production for Th1-cell therapy using negatively charged liposomes containing phosphatidylserine. Vaccine 2007, 25(29):5256-5262.
53. Schrama D., Reisfeld R.A., Becker J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5(2):147-159.
54. Gramatica A., et al. alphaEnv-decorated phosphatidylserine liposomes trigger phagocytosis of HIV-virus-like particles in macrophages. Nanomedicine 2014, 10(5):981-989.
55. Allon N., et al. A new liposome-based gene delivery system targeting lung epithelial cells using endothelin antagonist. J. Control. Release 2012, 160(2):217-224.
56. Khallou-Laschet J., et al. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010, 5(1):e8852.
57. Moore K.J., Sheedy F.J., Fisher E.A. Macrophages in atherosclerosis: A dynamic balance. Nat. Rev. Immunol. 2013, 13(10):709-721.
58. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 2010, 10(1):36-46.
59. Maiseyeu A., et al. Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. J. Lipid Res. 2009, 50(11):2157-2163.
60. Geelen T., et al. Internalization of paramagnetic phosphatidylserine-containing liposomes by macrophages. J. Nanobiotechnol. 2012, 10:37.
61. Kunjathoor V.V., et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 2002, 277(51):8-49982.
62. Maiseyeu A., et al. Detection of macrophages via paramagnetic vesicles incorporating oxidatively tailored cholesterol ester: an approach for atherosclerosis imaging. Nanomedicine 2010, 5:1341-1356.
63. Maiseyeu A., et al. In vivo targeting of inflammation-associated myeloid-related protein 8/14 via gadolinium immunonanoparticles. Arterioscler. Thromb. Vasc. Biol. 2012, 32:70-962.
64. Kee P., et al. Noninvasive detection of macrophages in atheroma using a radiocontrast-loaded phosphatidylserine-containing liposomal contrast agent for computed tomography. Mol. Imaging Biol. 2015, 17:328-336.
65. Ogawa M., et al. Development of 111In-labeled liposomes for vulnerable atherosclerotic plaque imaging. J. Nucl. Med. 2014, 55:20-115.
66. Lindner J.R., et al. Noninvasive ultrasound imaging of inflammation using microbubbles targeted to activated leukocytes. Circulation 2000, 102:2745-2750.
67. Christiansen J.P., et al. Noninvasive imaging of myocardial reperfusion injury using leukocyte-targeted contrast echocardiography. Circulation 2002, 105:1764-1767.
68. Behm C.Z., et al. Molecular imaging of endothelial vascular cell adhesion molecule-1 expression and inflammatory cell recruitment during vasculogenesis and ischemia-mediated arteriogenesis. Circulation 2008, 117:2902-2911.
69. Huang H., et al. Learning from biology: Synthetic lipoproteins for drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015, 7(3):298-314.
70. Allijn I.E., et al. Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano 2013, 7(11):9761-9770.
71. Briley-Saebo K.C., et al. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J. Am. Coll. Cardiol. 2011, 57(3):337-347.
72. Cheng Z., et al. Multifunctional nanoparticles: Cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338(6109):903-910.
73. Torchilin V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 2014, 13(11):813-827.
74. Nguyen T.H., et al. Manganese G8 dendrimers targeted to oxidation-specific epitopes: In vivo MR imaging of atherosclerosis. J. Magn. Reson. Imaging 2015, 41(3):797-805.
75. Mulder W.J., et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn. Reson. Med. 2007, 58(6):1164-1170.
76. Gianella A., et al. Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chem. Commun. (Camb.) 2013, 49(82):9392-9394.
77. Muller A., et al. Imaging atherosclerotic plaque inflammation via folate receptor targeting using a novel 18F-folate radiotracer. Mol. Imaging 2014, 13:1-11.
78. Cormode D.P., et al. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008, 4(9):1437-1444.
79. Duivenvoorden R., et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 2014, 5:3065.
80. Sinclair H., et al. OCT for the identification of vulnerable plaque in acute coronary syndrome. J. Am. Coll. Cardiol. Img. 2015, 8(2):198-209.
81. Mulder W.J., et al. Imaging and nanomedicine in inflammatory atherosclerosis. Sci. Transl. Med. 2014, 6(239):239 sr1.
82. Vucic E., et al. Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. J. Am. Coll. Cardiol. Img. 2011, 4(10):1100-1109.
83. Hyafil F., et al. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: A comparison with 18F-FDG PET/CT and histology. J. Nucl. Med. 2009, 50(6):959-965.
84. Tahara N., et al. 2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis. Nat. Med. 2014, 20(2):215-219.
85. Niu M., et al. Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin. Mol. Pharm. 2014, 11(12):4425-4436.
86. Yu S.S., et al. Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles. Mol. Pharm. 2013, 10(3):975-987.
87. Zheng B., et al. Predictors of plaque rupture within nonculprit fibroatheromas in patients with acute coronary syndromes: The prospect study. J. Am. Coll. Cardiol. Img. 2015, 8(10):1180-1187.
88. Motoyama S., et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-Up. J. Am. Coll. Cardiol. 2015, 66(4):337-346.
89. Joshi N.V., et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. Lancet 2014, 383(9918):705-713.
90. Irkle A., et al. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. Nat. Commun. 2015, 6:7495.
91. Bucerius J., et al. Arterial and fat tissue inflammation are highly correlated: A prospective 18F-FDG PET/CT study. Eur. J. Nucl. Med. Mol. Imaging 2014, 41(5):934-945.
92. Cai J., et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: Comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 2005, 112(22):3437-3444.
93. Kono H., et al. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J. Clin. Invest. 2010, 120(6):1939-1949.
94. Kool M., et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 2011, 34(4):527-540.
95. Sheedy F.J., et al. CD36 coordinates NLRP3 inflammasome activation by facilitating the intracellular nucleation from soluble to particulate ligands in sterile inflammation. Nat. Immunol. 2013, 14(8):812-820.
96. Friggeri A., et al. HMGB1 inhibits macrophage activity in efferocytosis through binding to the α(v)β(3)-integrin0. Am. J. Physiol. Cell Physiol. 2010, 299(6):C1267-C1276.
97. Apetoh L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13(9):1050-1059.
98. Spisek R., et al. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007, 109(11):4839-4845.
99. Rumore P.M., Steinman C.R. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J. Clin. Invest. 1990, 86(1):69-74.
100. Ueki S., et al. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood 2013, 121(11):2074-2083.
101. West A.P., Shadel G.S., Ghosh S. Mitochondria in innate immune responses. Nat. Rev. Immunol. 2011, 11(6):389-402.
102. Brinkmann V., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303(5663):1532-1535.
103. Leonard C.A., Schoborg R.V., Borel N. Damage/danger associated molecular patterns (damps) modulate chlamydia pecorum and c. trachomatis serovar e inclusion development in vitro. PLoS One 2015, 10(8):e0134943.
104. Oboki K., et al. IL-33 and airway inflammation. Allergy Asthma Immunol. Res. 2011, 3(2):81-88.
105. Foell D., et al. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 2007, 81(1):28-37.
106. Schaefer L. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr. Opin. Pharmacol. 2010, 10(2):185-190.
107. Yu J., et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc. Natl. Acad. Sci. U. S. A. 2015, 112(27):8260-8265.
108. Kim K.S., et al. Bioimaging of hyaluronate-interferon alpha conjugates using a non-interfering zwitterionic fluorophore. Biomacromolecules 2015.
109. Lam J., et al. Delivery of iPS-NPCs to the stroke cavity within a hyaluronic acid matrix promotes the differentiation of transplanted cells. Adv. Funct. Mater. 2014, 24(44):7053-7062.
110. Ravichandran K.S. Find-me and eat-me signals in apoptotic cell clearance: Progress and conundrums. J. Exp. Med. 2010, 207(9):1807-1817.
111. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: The importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 2005, 25(11):2255-2264.
112. Morelli A.E., Larregina A.T. Apoptotic cell-based therapies against transplant rejection: Role of recipient's dendritic cells. Apoptosis 2010, 15(9):1083-1097.
113. Tyurin V.A., et al. Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic 'eat-me' signals: Cleavage and inhibition of phagocytosis by Lp-PLA2. Cell Death Differ. 2014, 21(5):825-835.
114. Gardai S.J., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123(2):321-334.
115. Garg A.D., et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012, 31(5):1062-1079.
116. Zullig S., et al. Aminophospholipid translocase TAT-1 promotes phosphatidylserine exposure during C. elegans apoptosis. Curr. Biol. 2007, 17(11):994-999.
117. Uderhardt S., et al. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 2012, 36(5):834-846.
118. Audi S., et al. Understanding the in vivo uptake kinetics of a phosphatidylethanolamine-binding agent (99 m)Tc-Duramycin. Nucl. Med. Biol. 2012, 39(6):821-825.
119. Waiczies S., et al. Anchoring dipalmitoyl phosphoethanolamine to nanoparticles boosts cellular uptake and fluorine-19 magnetic resonance signal. Sci Rep 2015, 5:8427.
120. Chu C.T., et al. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat. Cell Biol. 2013, 15(10):1197-1205.
121. Yanamala N., et al. Structural re-arrangement and peroxidase activation of cytochrome c by anionic analogues of vitamin E, tocopherol succinate and tocopherol phosphate. J. Biol. Chem. 2014, 289(47):32488-32498.
122. Hazen S.L. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J. Biol. Chem. 2008, 283(23):15527-15531.
123. Briley-Saebo K., et al. Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: Progress and future directions. J. Cardiovasc. Transl. Res. 2014, 7(8):719-736.
124. Lu T., et al. Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome. Int. J. Cardiovasc. Imaging 2014, 30(1):221-231.
125. Miller Y.I., Tsimikas S. Oxidation-specific epitopes as targets for biotheranostic applications in humans: Biomarkers, molecular imaging and therapeutics. Curr. Opin. Lipidol. 2013, 24(5):426-437.
126. Wen S., et al. In vivo MRI detection of carotid atherosclerotic lesions and kidney inflammation in ApoE-deficient mice by using LOX-1 targeted iron nanoparticles. Nanomedicine 2014, 10(3):639-649.
127. Chu Z., et al. In vivo optical imaging of brain tumors and arthritis using fluorescent SapC-DOPS nanovesicles. J. Vis. Exp. 2014, 87.
128. Qi X., et al. Saposin C coupled lipid nanovesicles specifically target arthritic mouse joints for optical imaging of disease severity. PLoS One 2012, 7(3):e33966.
129. Wojton J., et al. SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget 2014, 5(20):9703-9709.
130. Zhao S., et al. SapC-DOPS nanovesicles as targeted therapy for lung cancer. Mol. Cancer Ther. 2015, 14(2):491-498.
131. Wojton J., et al. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol. Ther. 2013, 21(8):1517-1525.
132. Sulaiman M.K., et al. SapC-DOPS nanovesicles induce Smac- and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas. Mol. Cancer 2015, 14:78.
133. Konduru N.V., et al. Phosphatidylserine targets single-walled carbon nanotubes to professional phagocytes in vitro and in vivo. PLoS One 2009, 4(2):e4398.
134. Maiseyeu A., et al. Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. J. Lipid Res. 2009, 50:2157-2163.
135. Maiseyeu A., Bagalkot V. In vitro uptake of apoptotic body mimicking phosphatidylserine-quantum dot micelles by monocytic cell line. Nanoscale Res. Lett. 2014, 9:176.